<?xml version='1.0' encoding='utf-8'?>
<document id="28242239"><sentence text="Role of Toll-like receptor 4 in drug-drug interaction between paclitaxel and irinotecan in vitro."><entity charOffset="62-72" id="DDI-PubMed.28242239.s1.e0" text="paclitaxel" /><entity charOffset="77-87" id="DDI-PubMed.28242239.s1.e1" text="irinotecan" /><pair ddi="false" e1="DDI-PubMed.28242239.s1.e0" e2="DDI-PubMed.28242239.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28242239.s1.e0" e2="DDI-PubMed.28242239.s1.e1" /></sentence><sentence text="The bacterial receptor, Toll-like receptor (TLR) 4 mediates inflammatory responses and has been linked to a broad array of diseases" /><sentence text=" TLR4 agonists are being explored as potential treatments for cancer and other diseases" /><sentence text=" We have previously shown that activation of TLR4 by lipopolysaccharide (LPS) leads to down-regulation of drug metabolizing enzymes/transporters (DMETs), and altered pharmacokinetics/pharmacodynamics (PK/PD) of drugs" /><sentence text=" These changes can increase the risk of drug-drug interactions (DDIs) in patients on multiple medications" /><sentence text=" Clinically, DDI was observed for combination chemotherapy of paclitaxel (TLR4 ligand) and irinotecan"><entity charOffset="62-72" id="DDI-PubMed.28242239.s6.e0" text="paclitaxel" /><entity charOffset="91-101" id="DDI-PubMed.28242239.s6.e1" text="irinotecan" /><pair ddi="false" e1="DDI-PubMed.28242239.s6.e0" e2="DDI-PubMed.28242239.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28242239.s6.e0" e2="DDI-PubMed.28242239.s6.e1" /></sentence><sentence text=" To determine the role of TLR4 in DDI between paclitaxel and irinotecan in vitro, primary hepatocytes from TLR4-wild-type (WT) and mutant mice were pre-treated with paclitaxel, followed by irinotecan"><entity charOffset="46-56" id="DDI-PubMed.28242239.s7.e0" text="paclitaxel" /><entity charOffset="61-71" id="DDI-PubMed.28242239.s7.e1" text="irinotecan" /><entity charOffset="165-175" id="DDI-PubMed.28242239.s7.e2" text="paclitaxel" /><entity charOffset="189-199" id="DDI-PubMed.28242239.s7.e3" text="irinotecan" /><pair ddi="false" e1="DDI-PubMed.28242239.s7.e0" e2="DDI-PubMed.28242239.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28242239.s7.e0" e2="DDI-PubMed.28242239.s7.e1" /><pair ddi="false" e1="DDI-PubMed.28242239.s7.e0" e2="DDI-PubMed.28242239.s7.e2" /><pair ddi="false" e1="DDI-PubMed.28242239.s7.e0" e2="DDI-PubMed.28242239.s7.e3" /><pair ddi="false" e1="DDI-PubMed.28242239.s7.e1" e2="DDI-PubMed.28242239.s7.e1" /><pair ddi="false" e1="DDI-PubMed.28242239.s7.e1" e2="DDI-PubMed.28242239.s7.e2" /><pair ddi="false" e1="DDI-PubMed.28242239.s7.e1" e2="DDI-PubMed.28242239.s7.e3" /><pair ddi="false" e1="DDI-PubMed.28242239.s7.e2" e2="DDI-PubMed.28242239.s7.e2" /><pair ddi="false" e1="DDI-PubMed.28242239.s7.e2" e2="DDI-PubMed.28242239.s7.e3" /></sentence><sentence text=" Gene expression of DMETs was determined" /><sentence text=" Paclitaxel treatment increased the levels of irinotecan metabolites, SN-38 and SN-38 glucuronide (SN-38G) in TLR4-dependent manner"><entity charOffset="1-11" id="DDI-PubMed.28242239.s9.e0" text="Paclitaxel" /><entity charOffset="46-56" id="DDI-PubMed.28242239.s9.e1" text="irinotecan" /><entity charOffset="80-97" id="DDI-PubMed.28242239.s9.e2" text="SN-38 glucuronide" /><entity charOffset="99-105" id="DDI-PubMed.28242239.s9.e3" text="SN-38G" /><pair ddi="false" e1="DDI-PubMed.28242239.s9.e0" e2="DDI-PubMed.28242239.s9.e0" /><pair ddi="false" e1="DDI-PubMed.28242239.s9.e0" e2="DDI-PubMed.28242239.s9.e1" /><pair ddi="false" e1="DDI-PubMed.28242239.s9.e0" e2="DDI-PubMed.28242239.s9.e2" /><pair ddi="false" e1="DDI-PubMed.28242239.s9.e0" e2="DDI-PubMed.28242239.s9.e3" /><pair ddi="false" e1="DDI-PubMed.28242239.s9.e1" e2="DDI-PubMed.28242239.s9.e1" /><pair ddi="false" e1="DDI-PubMed.28242239.s9.e1" e2="DDI-PubMed.28242239.s9.e2" /><pair ddi="false" e1="DDI-PubMed.28242239.s9.e1" e2="DDI-PubMed.28242239.s9.e3" /><pair ddi="false" e1="DDI-PubMed.28242239.s9.e2" e2="DDI-PubMed.28242239.s9.e2" /><pair ddi="false" e1="DDI-PubMed.28242239.s9.e2" e2="DDI-PubMed.28242239.s9.e3" /></sentence><sentence text=" Paclitaxel-mediated induction of genes involved in irinotecan metabolism such as Cyp3a11 and Ugt1a1 was TLR4-dependent, while induction of the transporter Mrp2 was TLR4-independent"><entity charOffset="1-11" id="DDI-PubMed.28242239.s10.e0" text="Paclitaxel" /><entity charOffset="52-62" id="DDI-PubMed.28242239.s10.e1" text="irinotecan" /><pair ddi="false" e1="DDI-PubMed.28242239.s10.e0" e2="DDI-PubMed.28242239.s10.e0" /><pair ddi="false" e1="DDI-PubMed.28242239.s10.e0" e2="DDI-PubMed.28242239.s10.e1" /></sentence><sentence text=" These novel findings demonstrate that paclitaxel can affect irinotecan metabolism by a TLR4-dependent mechanism"><entity charOffset="39-49" id="DDI-PubMed.28242239.s11.e0" text="paclitaxel" /><entity charOffset="61-71" id="DDI-PubMed.28242239.s11.e1" text="irinotecan" /><pair ddi="false" e1="DDI-PubMed.28242239.s11.e0" e2="DDI-PubMed.28242239.s11.e0" /><pair ddi="false" e1="DDI-PubMed.28242239.s11.e0" e2="DDI-PubMed.28242239.s11.e1" /></sentence><sentence text=" This provides a new perspective towards evaluation of marketed drugs according to their potential to exert DDIs in TLR4-dependent manner" /><sentence text="" /></document>